Haemophilic patients with inhibitors to factor VIII or IX: Variables affecting treatment response

Haemophilia

Volumn 7, Issue 1, 2001, Pages 103-108

  Penner, J A ^a  

^a MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; ANTITHROMBIN III CONCENTRATE; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 INHIBITOR; BLOOD CLOTTING FACTOR 9; BLOOD CLOTTING FACTOR 9 COMPLEX; BLOOD CLOTTING FACTOR 9 CONCENTRATE; BLOOD CLOTTING FACTOR 9A; HEPARIN; HLA ANTIGEN; LUPUS ANTICOAGULANT; PHOSPHOLIPID; PHOSPHOLIPID ANTIBODY; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT BLOOD CLOTTING FACTOR 8;

ADULT; AGE; ANTIBODY DETECTION; ARTICLE; BLEEDING; BREAST FEEDING; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EXPOSURE; DRUG HALF LIFE; DRUG PURITY; DRUG RESPONSE; ETHNIC GROUP; GENE MUTATION; GENOTYPE; HEMARTHROSIS; HEMOPHILIA; HLA SYSTEM; HUMAN; IMMUNE STATUS; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; INCIDENCE; PATIENT CARE; PLACENTA CIRCULATION; PLASMAPHERESIS; POSTOPERATIVE CARE; PRIORITY JOURNAL; THROMBOGENESIS;

ANTIBODIES; FACTOR IX; FACTOR VIII; HEMOPHILIA A; HUMANS; TREATMENT OUTCOME;

EID: 0035131779     PISSN: 13518216     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2516.2001.00473.x     Document Type: Article

References (34)

1. Incidence of inhibitors in patients with severe and moderate hemophilia A treated with factor VIII concentrates
2. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs
3. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group
4. Inhibitors occur more frequently in African-American and Latino haemophiliacs
5. Prevalence of inhibitors in hemophilia A and B
6. A more uniform measurement of factor VIII inhibitors
7. Anti-factor VIII inhibitors and lupus anticoagulants in haemophilia A patients
8. 2 domain inhibit factor VIII binding to von Willebrand factor and to phosphatidylserine
9. Haemophilia A: Mutation type determines risk of inhibitor formation
10. HLA Class II profile: A weak determinant of factor VIII inhibitor development in severe haemophilia A
11. Loss of high-responder inhibitors in patients with severe hemophilia A and Human immunodeficiency virus type I infection
12. Absence of inhibitors in previously untreated patients with severe hemophilia A after exposure to a single intermediate purity factor VIII product
13. A higher than expected incidence of factor VIII Inhibitors in multi-transfused haemophilia A patients treated with an intermediate purity pasteurized factor VIII concentrate
14. Neoantigens and antibodies to factor VIII
15. 'Auto'-factor IX concentrates: A new therapeutic approach to treatment of hemophilia A patients with inhibitors
16. Activated prothrombin concentrate for patients with factor VIII inhibitors
17. Activated prothrombin complex concentrates in congenital and acquired haemorrhagic disorders
18. The use of factor VIII inhibitor bypassing activity product (FEIBA Immuno) for treatment of bleeding episodes in hemophiliacs with inhibitors
19. Factor VIII inhibitor bypassing activity
20. Anti-inhibitor coagulant complex (Autoplex®) for treatment of factor VIII inhibitors in hemophilia
21. The effect of activated prothrombin complex concentrate (FEIBA®) on joint and muscle bleeding in patients with Hemophilia A and antibodies to factor VIII
22. Autoplex® versus Proplex®: A controlled, double-blind study of effectiveness in acute hemarthroses in hemophiliacs with inhibitors to factor VIII
23. Antihaemophilic factor inhibitors management with prothrombin complex concentrates
24. Comparison between two concentrates with factor VIII inhibitor bypassing activity
25. Multicentre retrospective study on the utilization of FEIBA® in France in patients with factor VIII and IX inhibitors
26. Treatment of inhibitor patients with activated prothrombin complex concentrates
27. Continuous infusion of recombinant factor VIIa in patients with haemophilia and inhibitors. Experience in the Netherlands and Belgium
28. Prospective, randomized trial of two doses of rFVIIa in haemophilia patients with inhibitors undergoing surgery
29. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa NovoSeven in haemophiliacs with inhibitors
30. Measurement of active coagulation factors in Autoplex®-T with colorimetric active site-specific assay technology
31. Use of prothrombin complex concentrates in management of bleeding in hemophiliacs with inhibitors
32. Use of prothrombin complex concentrates and activated prothrombin complex concentrates as prophylactic therapy in haemophilia patients with inhibitors
33. Safety profile of porcine factor VIII and its use as hospital and home therapy for patients with hemophilia A and inhibitors